WebNov 15, 2024 · UGA Alum and Inbrain.ai Founder Jason Schubert joins the podcast to share the journey of building and exiting his people-based insights and survey platform startup. On the heels of recently being acquired by the world's largest first-party data platform for insights, Dynata, Jason talks through his thought process of the acquisition, points of … WebAug 3, 2024 · The addition of inBrain.ai’s consumer engagement and survey platform ensures Dynata continues to have the right mix of data, technology, and tools to meet the growing demand for actionable insights while also maintaining an optimal panelist experience. inBrain.ai’s mobile platform strengthens Dynata’s rich first-party data, …
Unity SDK inBrain.ai
WebinBrain.ai Jan 2024 - Jun 2024 6 months. Atlanta, GA, United States • Updated and maintained Zap Surveys functionality, including UI interactions and network calls • Built out inBrain’s ... WebJul 1, 2024 · Inbrain’s high resolution implants will be combined with the company’s AI-powered data analytic platform, which will be used to continually monitor brain signals in patients. This, Aguilar says, will allow clinicians to build a more complete picture of the individual’s brain, and provide bespoke treatments for conditions like epilepsy. shantay wells uconn
Georghy Sariman - Digital Designer - inBrain LinkedIn
WebMar 17, 2024 · inBrain.ai ★★★★★ Click to Rate or Add Salary Add Interview Add Benefits Glassdoor has 1 inBrain.ai reviews submitted anonymously by inBrain.ai employees. Read employee reviews and ratings on Glassdoor to decide if inBrain.ai is right for you. Argentina Australia België (Nederlands) Belgique (Français) Brasil Canada (English) Canada (Français) WebinBrain.ai was acquired by Dynata in 2024. inBrain today continues to help companies scale their in-app and web monetization with a large suite of … WebJul 20, 2024 · INBRAIN Neuroelectronics Secures $17 Million in Series A Funding for First AI-Powered Graphene-Brain Interface Funding enables company to advance first-in-human studies for its flagship product, a less-invasive neuromodulation device for treating neurological conditions using artificial intelligence and graphene electrodes shant barsoumian